{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:02:02Z","timestamp":1778896922556,"version":"3.51.4"},"reference-count":32,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"Bristol-Myers Squibb","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2021,7,29]]},"DOI":"10.1080\/10428194.2021.1910686","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T09:55:44Z","timestamp":1621590944000},"page":"2169-2176","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Postinfusion monitoring costs by site of care for patients with relapsed\/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials"],"prefix":"10.1080","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika Parisi","family":"Jun","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lymp","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"BluePath Solutions, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"November","family":"McGarvey","sequence":"additional","affiliation":[{"name":"BluePath Solutions, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Gitlin","sequence":"additional","affiliation":[{"name":"BluePath Solutions, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Keating","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Godwin","sequence":"additional","affiliation":[{"name":"Providence Cancer Center, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"#cr-split#-CIT0001.1","unstructured":"US Cancer Statistics Working Group. US Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016) [Internet]. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention"},{"key":"#cr-split#-CIT0001.2","unstructured":"2019. [cited 2020 Oct 6]. Available from: https:\/\/gis.cdc.gov\/Cancer\/USCS\/DataViz.html"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.197"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1229773"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.15605"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.25270\/jcp.2018.10.00039"},{"key":"#cr-split#-CIT0013.1","unstructured":"The ASCO Post. ASH 2017: JULIET trial: 6-month analysis of tisagenlecleucel in relapsed\/refractory DLBCL shows sustained responses [Internet]. Huntington (NY): Harborside"},{"key":"#cr-split#-CIT0013.2","unstructured":"2017. [cited 2020 Oct 6]. Available from: http:\/\/www.ascopost.com\/News\/58349."},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127566"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072"},{"key":"CIT0016","unstructured":"Strengthening the Reporting of Observational studies in Epidemiology (STROBE). STROBE statement \u2013 Checklist of items that should be included in reports of cohort studies. [Internet]. 2020. [cited 2020 Oct 6]. Available from: https:\/\/www.strobe-statement.org\/fileadmin\/Strobe\/uploads\/checklists\/STROBE_checklist_v4_cohort.pdf"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000164543.14619.00"},{"key":"CIT0019","unstructured":"IBM Micromedex. RED BOOK [Internet]. Armonk (NY): IBM; 2019. [cited 2020 Oct 6]. Available from: https:\/\/www.ibm.com\/watson\/health\/provider-client-training\/micromedex-red-book\/."},{"key":"CIT0020","unstructured":"Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule [Internet]. Baltimore (MD): US Centers for Medicare & Medicaid Services; 2020. [cited 2020 Oct 6]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched."},{"key":"CIT0021","unstructured":"Centers for Medicare & Medicaid Services. Durable Medical Equipment (DME) Center [Internet]. Baltimore (MD): US Centers for Medicare & Medicaid Services; 2019. [cited 2020 Oct 6]. Available from: https:\/\/www.cms.gov\/Center\/Provider-Type\/Durable-Medical-Equipment-DME-Center."},{"key":"CIT0022","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule [Internet]. Baltimore (MD): US Centers for Medicare & Medicaid Services; 2020. [cited 2020 Oct 6]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched."},{"key":"CIT0023","unstructured":"Centers for Medicare & Medicaid Services. Hospital Outpatient PPS [Internet]. Baltimore (MD): US Centers for Medicare & Medicaid Services; 2020. [cited 2020 Oct 6]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/HospitalOutpatientPPS."},{"key":"CIT0024","unstructured":"American Hospital Association. Fact sheet: underpayment by Medicare and Medicaid [Internet]. Chicago (IL): American Hospital Association; 2020. [cited 2020 Oct 6]. Available from: https:\/\/www.aha.org\/system\/files\/media\/file\/2020\/01\/2020-Medicare-Medicaid-Underpayment-Fact-Sheet.pdf."},{"key":"CIT0025","unstructured":"Leavitt Partners. Cancer treatment costs are consistently lower in the community setting versus the hospital outpatient department [Internet]. Salt Lake City (UT): Leavitt Partners; 2017. [cited 2020 Oct 6]. Available from: https:\/\/leavittpartners.com\/whitepaper\/cancer-treatment-costs-are-consistently-lower-in-the-community-setting-versus-the-hospital-outpatient-department\/."},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701191"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8037"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0977"},{"key":"CIT0029","unstructured":"Institute for Clinical and Economic Review. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value [Internet]. Boston (MA): Institute for Clinical and Economic Review; 2018. [cited 2020 Oct 6]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/07\/ICER_CAR_T_Final_Evidence_Report_032318.pdf."},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0035"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2021.1910686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T02:05:13Z","timestamp":1685585113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2021.1910686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,7,29]]}},"alternative-id":["10.1080\/10428194.2021.1910686"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2021.1910686","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}